Leveraging human genetic data to investigate the cardiometabolic effects of glucose-dependent insulinotropic polypeptide signalling. by Karhunen, V et al.
SHORT COMMUNICATION
Leveraging human genetic data to investigate the cardiometabolic
effects of glucose-dependent insulinotropic polypeptide signalling
Ville Karhunen1,2,3 & Iyas Daghlas4 & Verena Zuber1,5 & Marijana Vujkovic6,7 & Anette K. Olsen8 &
Lotte Bjerre Knudsen8 & William G. Haynes9,10 & Joanna M. M. Howson9 & Dipender Gill1,9,11,12
Received: 1 April 2021 /Accepted: 22 July 2021
# The Author(s) 2021
Abstract
Aims/hypothesis The aim of this study was to leverage human genetic data to investigate the cardiometabolic effects of glucose-
dependent insulinotropic polypeptide (GIP) signalling.
Methods Data were obtained from summary statistics of large-scale genome-wide association studies. We examined whether
genetic associations for type 2 diabetes liability in the GIP and GIPR genes co-localised with genetic associations for 11
cardiometabolic outcomes. For those outcomes that showed evidence of co-localisation (posterior probability >0.8), we
performed Mendelian randomisation analyses to estimate the association of genetically proxied GIP signalling with risk of
cardiometabolic outcomes, and to test whether this exceeded the estimate observed when considering type 2 diabetes liability
variants from other regions of the genome.
Results Evidence of co-localisation with genetic associations of type 2 diabetes liability at both the GIP and GIPR genes was
observed for five outcomes. Mendelian randomisation analyses provided evidence for associations of lower genetically proxied
type 2 diabetes liability at the GIP and GIPR genes with lower BMI (estimate in SD units −0.16, 95% CI −0.30, −0.02), C-
reactive protein (−0.13, 95% CI −0.19, −0.08) and triacylglycerol levels (−0.17, 95% CI −0.22, −0.12), and higher HDL-
cholesterol levels (0.19, 95% CI 0.14, 0.25). For all of these outcomes, the estimates were greater in magnitude than those
observed when considering type 2 diabetes liability variants from other regions of the genome.
Conclusions/interpretation This study provides genetic evidence to support a beneficial role of sustained GIP signalling on
cardiometabolic health greater than that expected from improved glycaemic control alone. Further clinical investigation is
warranted.
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Glucose-dependent insulinotropic polypeptide (or gastric inhibi-
tory polypeptide, GIP) is an incretin peptide that stimulates insulin
secretion after oral nutrient intake. Both GIP and glucagon-like
peptide 1 (GLP-1) are involved in regulating energy homeostasis
[1]. GLP-1 agonism is an established pharmacological target for
treating type 2 diabetes and obesity, however it is unclear whether
pharmacological GIP agonism represents a similar therapeutic
opportunity [2]. Here, we leverage human genetic data to inves-
tigate the potential of targeting GIP signalling for the treatment of
cardiometabolic disease.
Methods
Overall study designWe investigated whether genetic associ-
ations for type 2 diabetes liability co-localised with genetic
associations for 11 cardiometabolic outcomes (Table 1) at
the GIP and GIPR genes. For those outcomes that showed
evidence for co-localisation, we performed Mendelian
randomisation (MR) analyses to investigate the association
of genetically proxied glucose-dependent insulinotropic poly-
peptide (GIP) signalling with the cardiometabolic outcomes,
and whether these estimates are greater than that expected
from reduced type 2 diabetes liability alone. Further details
are given in the electronic supplementary material (ESM)
Methods.
Genetic association estimates Genetic association estimates
for SNPs with type 2 diabetes liability, HbA1c levels and the
considered cardiometabolic outcomes were obtained from
genome-wide association study (GWAS) summary statistics
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(Table 1). The individual studies had previously obtained rele-
vant ethical approval and participant consent.
Statistical analyses We used co-localisation analysis to
compare the genetic association signals for type 2 diabetes
liability and each cardiometabolic outcome for variants within
GIP andGIPR. The ‘coloc’method applied here examines the
likelihood of a shared causal variant for both exposure and
outcome [3]. Co-localisation was declared if the posterior
probability (PP) for a model with a shared causal variant
exceeded 0.8 (ESM Methods). For the outcomes where co-
localisation analysis suggested separate causal variants for
type 2 diabetes liability and the outcome, co-localisation was
re-run after excluding the variants that were in linkage
disequilibrium (r2 > 0.2) with the most likely causal SNP
for the outcome (ESM Methods).
The outcomes that showed evidence for co-localisation
were taken forward for MR analysis. In MR, genetic variants
are used as proxies for an exposure (here, GIP signalling) to
examine its potential causal effect on an outcome, and the
method can be applied to investigate drug effects [4]. Given
the known role of GIP signalling on improving glycaemic
control in healthy individuals [5], we identified genetic prox-
ies as SNPs located within GIP and GIPR genes that
associated with type 2 diabetes liability at p < 5 × 10−6 and
also associated with HbA1c levels at p < 0.05 with a concor-
dant direction, and applied clumping by excluding variants
with r2 > 0.1 with the lead SNP. Prior filtering of genetic
variants was applied based on the co-localisation analysis, so
that variants exhibiting potential horizontal pleiotropy were
removed (ESM Methods).
The main MR analysis was conducted by pooling the
associations of all proxy variants from both the GIP and
GIPR genes using the random-effects inverse-variance
weighted method. To compare the associations of geneti-
cally proxied GIP signalling with improved glycaemic
control more generally, we compared the main MR results
to that of a general reduction in type 2 diabetes liability and
improved glycaemic control using variants across the
genome that associated with type 2 diabetes liability at p
< 5 × 10−6 and HbA1c levels at p < 0.05 with a concor-
dant direction, excluding variants within GIP and GIPR
(ESM Methods). In sensitivity analysis, we performed
MR using exposure genetic association estimates for
HbA1c levels, rather than type 2 diabetes liability (ESM
Methods). As a final sensitivity analysis, we performed
MR using functionally relevant variants or expression
quantitative trait loci (eQTL, ESM Methods).
Table 1 Genome-wide associa-
tion studies used to obtain the
summary statistics
Phenotype Sample size Cases Controls Sourcea
Exposures
Type 2 diabetesb 74,124 824,006 Mahajan et al, 2018
Type 2 diabetesc 228,499 1,178,783 Vujkovic et al, 2020




Chronic kidney disease 64,164 561,055 Wuttke et al, 2019
Coronary artery disease 60,801 123,504 Nikpay et al, 2015
HF 47,309 930,014 Shah et al, 2020
Ischaemic stroke 34,217 406,111 Malik et al, 2018
Cardiometabolic traits
Alanine aminotransferase 344,136 Neale lab 2020
BMI 484,680 Pulit et al. 2018
CRP 343,524 Neale lab 2020
Systolic BP 745,820 Evangelou et al. 2018
Lipids
HDL-C 315,133 Neale lab 2020
LDL-C 343,621 Neale lab 2020
Triacylglycerol 343,992 Neale lab 2020
a The references for the original studies are given in the ESM
bUsed for co-localisation analysis
c Used for MR analysis




Co-localisation analysis showed evidence of a shared causal vari-
ant for type 2 diabetes liability and eight outcomes at the GIP
gene, and six outcomes at the GIPR gene (PP > 0.8, ESM
Table 1). For the five outcomes of heart failure (HF), BMI, C-
reactive protein (CRP) levels, HDL-cholesterol (HDL-C) and
triacylglycerols, there was evidence for Co-localisation also
protects at both GIP and GIPR.
The co-localising outcomes were taken forward to MR
analysis, where increased genetically proxied GIP signalling
(using variants given in ESM Tables 2–4) was associated with
lower BMI (estimate and its 95% CI in SD units per halving
the genetically proxied odds of type 2 diabetes = −0.16
[−0.30, −0.02]), CRP levels (−0.13 [−0.19, −0.08]) and triac-
ylglycerol levels (−0.17 [−0.22, −0.12]), and higher HDL-C
levels (0.19 [0.14, 0.25]; Fig. 1; ESM Table 4). For these
outcomes, the MR estimates were similar when using variants
from GIP and GIPR genes separately (Fig. 1; ESM Table 4).
The MR estimate for risk of HF was inconclusive (OR per
halving the odds of type 2 diabetes [95% CI] = 1.05 [0.65,
1.70]; Fig. 1; ESM Table 4). There was evidence of a larger
association of genetically proxied GIP signalling compared
with genetically proxied reduced type 2 diabetes liability more
generally for CRP, HDL-C and triacylglycerol levels (all p <
0.001), but not strongly for BMI (p = 0.07, ESM Table 4).
Similar results were obtained when using variant–exposure
associations for HbA1c levels rather than for type 2 diabetes
liability (Pearson correlation of the MR β estimates = 0.99;
ESM Table 5; ESM Figs 1 and 2), and when using missense
variant rs2291725 in GIP or eQTL variant rs12709891 in
GIPR (ESM Tables 2 and 6; ESM Fig. 3).
For those outcomes that co-localised only at one genomic
locus, there was evidence for association between genetically
proxied GIP signalling and lower risk of coronary artery
disease (OR [95% CI] = 0.51 [0.37, 0.71]), lower alanine
aminotransferase (−0.13 [−0.20, −0.07]) and lower systolic
BP (−0.18 [−0.25, −0.12]) at the GIP locus, with all these
the estimates exceeding those obtained for reduced type 2
diabetes liability more generally (ESM Fig. 4; ESM Table 7).
Fig. 1 (a) ORs for risk of HF and (b–e) effect size estimates (MR β
coefficients for BMI [b], CRP [c], HDL-C [d] and triacylglycerol levels
[e], all in SD units) and their 95% CIs per halving the odds of genetically
proxied type 2 diabetes liability. The dashed vertical line represents the




Our genetic analyses using human data provide consistent
support for favourable effects of sustained GIP signalling on
BMI, CRP, HDL-C and triacylglycerol levels. The MR esti-
mates for CRP, HDL-C and triacylglycerol levels exceeded
and were statistically heterogeneous to those obtained for
reduced type 2 diabetes liability more generally, suggesting
additional mechanisms specific to GIP signalling. The MR
results were replicated in analyses restricted to functionally
relevant variants.
Although a dual GIP and GLP-1 receptor agonist has
shown efficacy for glucose control and weight loss in clinical
trials of patients with type 2 diabetes [6, 7], it is not clear how
much of the observed effect is specifically attributable to GIP
agonism. Preclinical studies have supported that sustained
GIP receptor (GIPR) agonism prevents weight gain and
enhances weight loss in diet-induced obese mice [8, 9]. Our
analyses using human genetic data provide further comple-
mentary evidence of the beneficial cardiometabolic effects of
sustained GIP signalling.
We observed discrepancy in the MR estimates for HF risk
that were generated when considering the GIP gene (lower
risk) as compared with the GIPR gene (higher risk).
Although a cardiovascular outcomes trial of dipeptidyl pepti-
dase 4 inhibition with saxagliptin found increased
hospitalisation rates for HF [10], this was not found for
sitagliptin [11]. Further work is required to ascertain whether
our findings offer any mechanistic or clinical insight in this
regard.
The use of randomly allocated genetic variants to proxy
drug effects in the MR paradigm is more robust to environ-
mental confounding that can hinder causal inference in obser-
vational studies [4]. We selected the genetic proxies for
sustained GIP signalling based on its known biological effects
in healthy individuals, namely improved glycaemic control
and reduced liability to type 2 diabetes [5]. Previous work
selected a variant to proxy GIP signalling based on its relation
to fasting GIP levels, and in contrast to our current findings
produced MR results to support a detrimental effect of GIP
signalling on coronary artery disease risk [12]. Further work is
required to clarify how different genetic variants at the GIPR
gene might relate to GIP signalling and its consequent down-
stream metabolic effects.
Our work has limitations. The genetic associations
were obtained from GWAS on mainly European ancestry
individuals, and these results may not generalise to other
ancestries. The findings do not extend to effects of other
glucose-lowering medications that indirectly alter GIP
signalling, and may not be applicable to individuals with
diabetes, in whom the physiological effects of GIP signal-
ling may be altered [13]. Finally, the genetic variants
employed as instruments proxy the effect of lifelong
alterations in GIP signalling and therefore the MR results
should not be directly extrapolated to quantitatively esti-
mate the clinical effect of short-term GIPR agonism [4].
Of relevance, recent evidence has supported that long-
term GIPR agonism desensitises adipocyte GIPR activity
in a manner resembling acute GIPR antagonism [8].
In conclusion, by leveraging human genetic data, we
provide evidence of favourable effects of sustained GIP
signalling on BMI, CRP, HDL-C and triacylglycerol levels.
These results support further clinical investigation of GIP
agonism as a therapeutic target for cardiometabolic disease.
Supplementary Information The online version contains peer-reviewed
but unedited supplementary material available at https://doi.org/10.1007/
s00125-021-05564-7.
Data availability All data used in this study are publicly available. The
scripts for the analysis are available at: https://github.com/vkarhune/
GeneticallyProxiedGIP.
Funding VK and DG are supported by the British Heart Foundation
Centre of Research Excellence (RE/18/4/34215) at Imperial College
London. DG is supported by a National Institute for Health Research
Clinical Lectureship at St George’s, University of London (CL-2020-
16-001). VK is supported by the Academy of Finland Profi 5 funding
for mathematics and AI: data insight for high dimensional dynamics and
the Academy of Finland [Project 312123], and European Union’s
Horizon 2020 research and innovation programme under grant agreement
no. 848158.
Authors’ relationships and activities AKO, LBK,WGH and JMMH are
employed full-time by Novo Nordisk and own minor employee-based
stock. DG is employed part-time by Novo Nordisk. Novo Nordisk
markets several GLP-1 based drugs for the treatment of diabetes and/or
obesity, and has a GIP based compound in clinical development. The
remaining authors declare that there are no relationships or activities that
might bias, or be perceived to bias, their work.
Contribution statement VK and DG designed the study. VK conducted
all statistical analyses. VK and DG drafted the manuscript. All authors
interpreted the results, participated in critical revision of the manuscript,
and approved the final version to be published. DG and VK take respon-
sibility for the contents of the article.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing, adap-
tation, distribution and reproduction in any medium or format, as long as
you give appropriate credit to the original author(s) and the source,
provide a link to the Creative Commons licence, and indicate if changes
were made. The images or other third party material in this article are
included in the article's Creative Commons licence, unless indicated
otherwise in a credit line to the material. If material is not included in
the article's Creative Commons licence and your intended use is not
permitted by statutory regulation or exceeds the permitted use, you will
need to obtain permission directly from the copyright holder. To view a
copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
Diabetologia
References
1. Gribble FM, Reimann F (2019) Function and mechanisms of
enteroendocrine cells and gut hormones in metabolism. Nat Rev
Endocrinol 15(4):226–237. https://doi.org/10.1038/s41574-019-
0168-8
2. Nauck MA, Meier JJ (2018) Incretin hormones: their role in health
and disease. Diabetes Obes Metab 20(S1):5–21. https://doi.org/10.
1111/dom.13129
3. Giambartolomei C, Vukcevic D, Schadt EE et al (2014) Bayesian
test for Colocalisation between pairs of genetic association studies
using summary statistics. PLoS Genet 10(5):1–15. https://doi.org/
10.1371/journal.pgen.1004383
4. Gill D, Georgakis M, Walker V et al (2021) Mendelian randomi-
zation for studying the effects of perturbing drug targets [version 2;
peer review: 3 approved, 1 approved with reservations]. Wellcome
Open Res 6(16). https://doi.org/10.12688/wellcomeopenres.16544.
2
5. Bailey CJ (2020) GIP analogues and the treatment of obesity-diabe-
tes. Peptides 125:170202. https://doi.org/10.1016/j.peptides.2019.
170202
6. Frías JP, Davies MJ, Rosenstock J et al (2021) Tirzepatide versus
Semaglutide once weekly in patients with type 2 diabetes. N Engl J
Med. https://doi.org/10.1056/NEJMoa2107519
7. Rosenstock J, Wysham C, Frías JP et al (2021) Efficacy and safety
of a novel dual GIP and GLP-1 receptor agonist tirzepatide in
patients with type 2 diabetes (SURPASS-1): a double-blind,
randomised, phase 3 trial. Lancet 398(10295):143–155. https://
doi.org/10.1016/S0140-6736(21)01324-6
8. Killion EA, Chen M, Falsey JR et al (2020) Chronic glucose-
dependent insulinotropic polypeptide receptor (GIPR) agonism
desensitizes adipocyte GIPR activity mimicking functional GIPR
antagonism. Nat Commun 11(1):1–17. https://doi.org/10.1038/
s41467-020-18751-8
9. Mroz PA, Finan B, Gelfanov V et al (2019) Optimized GIP analogs
promote body weight lowering in mice through GIPR agonism not
antagonism. Mol Metab 20:51–62. https://doi.org/10.1016/j.
molmet.2018.12.001
10. Scirica BM, Bhatt DL, Braunwald E et al (2013) Saxagliptin and
cardiovascular outcomes in patients with type 2 diabetes mellitus. N
Engl J Med 369(14):1317–1326. https://doi.org/10.1056/
NEJMoa1307684
11. Green JB, Bethel MA, Armstrong PW et al (2015) Effect of
Sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl
J Med 373(3):232–242. https://doi.org/10.1056/NEJMoa1501352
12. Jujić A, Atabaki-Pasdar N, Nilsson PM et al (2020) Glucose-
dependent insulinotropic peptide and risk of cardiovascular events
and mortality: a prospective study. Diabetologia 63:1043–1054.
https://doi.org/10.1007/s00125-020-05093-9
13. Bergmann NC, Gasbjerg LS, Heimbürger SM et al (2020) No acute
effects of exogenous glucose-dependent Insulinotropic polypeptide
on energy intake, appetite, or energy expenditure when added to
treatment with a long-acting glucagon-like peptide 1 receptor
agonist in men with type 2 diabetes. Diabetes Care 43(3):588–
596. https://doi.org/10.2337/dc19-0578
Publisher’s note Springer Nature remains neutral with regard to jurisdic-
tional claims in published maps and institutional affiliations.
Diabetologia
